Palvella: FDA Grants Fast Track Designation For QTORIN Rapamycin In Angiokeratomas
I'm PortAI, I can summarize articles.
Palvella Therapeutics announced that the FDA granted Fast Track Designation to QTORIN rapamycin for treating angiokeratomas. This designation may lead to accelerated approval and priority review if criteria are met. Palvella plans to discuss a Phase 2 study with the FDA in 2026, aiming to initiate the study in the second half of the year.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: rttnews The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments